Literature DB >> 2285291

In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases.

M D Kitzis1, N Liassine, B Ferré, L Gutmann, J F Acar, F Goldstein.   

Abstract

The activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases were studied. All compounds were affected by these enzymes, especially by the SHV derivatives. Except for ceftibuten, the compounds with the greatest intrinsic activity were more affected by the presence of these enzymes than were older compounds with moderate intrinsic activity.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2285291      PMCID： PMC171925          DOI： 10.1128/AAC.34.9.1783

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam.

Authors:  L Gutmann; M D Kitzis; D Billot-Klein; F Goldstein; G Tran Van Nhieu; T Lu; J Carlet; E Collatz; R Williamson
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

2.  Comparative study of a novel plasmid-mediated beta-lactamase, CAZ-2, and the CTX-1 and CAZ-1 enzymes conferring resistance to broad-spectrum cephalosporins.

Authors:  C M Chanal; D L Sirot; R Labia; A Petit; A Morand; J L Sirot; R A Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors.

Authors:  M D Kitzis; D Billot-Klein; F W Goldstein; R Williamson; G Tran Van Nhieu; J Carlet; J F Acar; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

6.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

7.  Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes.

Authors:  W Sougakoff; S Goussard; G Gerbaud; P Courvalin
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

8.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

9.  Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae.

Authors:  C Brun-Buisson; P Legrand; A Philippon; F Montravers; M Ansquer; J Duval
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

10.  Translocation of sequences encoding antibiotic resistance from the chromosome to a receptor plasmid in Salmonella ordonez.

Authors:  A Labigne-Roussel; G Gerbaud; P Courvalin
Journal:  Mol Gen Genet       Date:  1981
View more
  14 in total

Review 1.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

3.  Activities of oral antibiotics on Providencia strains isolated from institutionalized elderly patients with urinary tract infections.

Authors:  G Cornaglia; S Frugoni; A Mazzariol; E Piacentini; A Berlusconi; R Fontana
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 4.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 5.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 6.  Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.

Authors:  G L Kearns; R A Young
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

Review 7.  Cefetamet pivoxil clinical pharmacokinetics.

Authors:  R A Blouin; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

Review 8.  Origin and impact of plasmid-mediated extended-spectrum beta-lactamases.

Authors:  A Philippon; G Arlet; P H Lagrange
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

Review 9.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

10.  Antibacterial properties of Ro 40-6890, a broad-spectrum cephalosporin, and its novel orally absorbable ester, Ro 41-3399.

Authors:  P Angehrn; P Hohl; C Hubschwerlen; M Page; R Then
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.